Arovella Therapeutics (ASX:ALA) Other Long-Term Liabilities: A$0.04 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Arovella Therapeutics Other Long-Term Liabilities?

Arovella Therapeutics ASX:ALA -3.23% Other Long-Term Liabilities is A$0.04 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Arovella Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2025 was A$0.04 Mil.

Arovella Therapeutics's quarterly other long-term liabilities declined from Dec. 2024 (A$0.02 Mil) to Jun. 2025 (A$-0.00 Mil) but then increased from Jun. 2025 (A$-0.00 Mil) to Dec. 2025 (A$0.04 Mil).

Arovella Therapeutics's annual other long-term liabilities increased from Jun. 2023 (A$0.01 Mil) to Jun. 2024 (A$0.02 Mil) but then declined from Jun. 2024 (A$0.02 Mil) to Jun. 2025 (A$-0.00 Mil).

Arovella Therapeutics Other Long-Term Liabilities Related Terms

Arovella Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Arovella Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics Other Long-Term Liabilities Chart

Arovella Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.02 -0.00

Arovella Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 0.02 -0.00 0.04

Arovella Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of A$0.04 Mil mean?
Arovella Therapeutics (ASX:ALA) has a Other Long-Term Liabilities of A$0.04 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Arovella Therapeutics and its competitors.
Is Arovella Therapeutics' Other Long-Term Liabilities too high?
Arovella Therapeutics' current Other Long-Term Liabilities is A$0.04 Mil.
How does Arovella Therapeutics' Other Long-Term Liabilities compare to VRTX and REGN?
Arovella Therapeutics' Other Long-Term Liabilities of A$0.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Arovella Therapeutics and its competitors. Arovella Therapeutics's current Other Long-Term Liabilities is A$0.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current Other Long-Term Liabilities of A$0.04 Mil. The current Other Long-Term Liabilities is A$0.04 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current Other Long-Term Liabilities is A$0.04 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arovella Therapeutics Business Description

Other Exchanges E4NA:Germany
Address 84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.